Summit Therapeutics plc Summit's Pipeline Expands With Series Of New Mechanism Antibiotics Targeting Enterobacteriaceae
April 03 2019 - 7:00AM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
('Summit' or the 'Company')
Summit's Pipeline Expands with Series of New Mechanism Antibiotics
Targeting Enterobacteriaceae
-- Data to be Presented in Oral Session at ECCMID 2019
Oxford, UK, and Cambridge, MA, US, 3 April 2019 -- Summit Therapeutics
plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic
innovation, today announces the expansion of its pipeline with a series
of new mechanism antibiotics, DDS-04, which targets Enterobacteriaceae.
Key data from this series will be presented in an oral session at the
29(th) European Congress of Clinical Microbiology & Infectious Diseases
('ECCMID'), taking place 13-16 April 2019 in Amsterdam.
"The DDS-04 series provides us with a major opportunity to improve
patient outcomes across several body sites where Enterobacteriaceae
cause infection," said Dr David Roblin, President of R&D of Summit. "We
look forward to developing the programme to show compelling clinical and
economic data that offer significant advantages over standard of care
for the patients in need."
Summit's DDS-04 series of new mechanism antibiotic compounds acts
specifically on Enterobacteriaceae via LolCDE, an unexploited bacterial
target. It is the first project to emerge from the Company's ESKAPE
pathogen programme. Enterobacteriaceae are a family of Gram-negative
bacteria, which include the critical threats Klebsiella pneumoniae and
Escherichia coli. These bacteria are responsible for a large number of
severe and often deadly infections of the bloodstream, lungs and urinary
tract. The DDS-04 series has shown activity across a global panel of K.
pneumoniae and E. coli strains, including strains resistant to current
standard of care treatments.
Details of the presentation are as follows:
Date: 14 April 2019
Time: 1:42pm CEST
Session: Novel antimicrobial agents and discovery strategies
Location: Hall M
Title: Novel Small-Molecule Inhibitors of Bacterial Lipoprotein
Transport with Potent Antimicrobial Activity against Enterobacteriaceae
https://www.globenewswire.com/Tracker?data=HFcHzhpbNVsXZKQDxEeIUFq23t9hUrAybdjmN4JgK5WrYh2KSRaZMP3ykFqthYkSzvwzvY2II3vnpWSCEXFqZLtG-0BJ5g-ZeA1MTvbfGbfVmgugA_7wiWhwqIrHR7TPjZIFbSQVTKGEMKFtv21nNwExzdRiFxijDmFk804wG2o1A-vEmt_I9QrU1PyLo_AvXJkEPxCsXSCPpDnPnnarKMGjYO9zqRNH-jlHtLOqqileVu8l1Cgae2WDmC6GKF_w1OyPz1nu-5-rpOnFxHN0t5APHt3FyxGuXeK6-t6XS85HlksF4N1cOiYBsNc1yvw1k43KUuiAwGm0g7Pa-EgyHp88HM376LHLZD6R4Ba-3IpBlamT0oVpCWIFAaCdxbxKrh8Perp6y9aZcjN7XCrqDN4ybOswvj0bOMmAno2Lf2-Zd01nR3Kqs_BBOzJfYD8OUPQq0sdrpcPdM_075GmnVkICLQuBNZbbbxJSwdjUo-g=
Authors: E. Breidenstein, O. Abdulle, T. Avis, C. Charrier, C. Ciardullo,
C. Coward, T. Duffy, N. Khan, C. Mason, P. Meo and D. Powell
About Enterobacteriaceae
Enterobacteriaceae are a family of Gram-negative bacteria responsible
for a large number of severe and often deadly infections of the
bloodstream, lungs and urinary tract. Increasing resistance of
Enterobacteriaceae has rendered many marketed antibiotics ineffective
against these bacteria. Two of the most alarming antibiotic resistance
trends are extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae and carbapenem-resistant Enterobacteriaceae (CRE).
ESBL is an enzyme that allows bacteria to become resistant to a wide
variety of penicillin and cephalosporin antibiotics. ESBL-producing
Enterobacteriaceae account for an estimated 26,000 infections annually
in the US with 1,700 deaths, according to the US Centers for Drug
Control and Prevention ('CDC'). CRE are resistant to nearly all existing
antibiotics, including carbapenems which are considered the antibiotics
of last resort. CRE account for an estimated 9,000 infections per year
in the US and 600 deaths, according to the CDC.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of care
for the benefit of patients and create value for payors and healthcare
providers. We are currently developing new mechanism antibiotics for
infections caused by C. difficile, N. gonorrhoeae and ESKAPE pathogens.
We are using our proprietary Discuva Platform to expand our pipeline.
For more information, visit www.summitplc.com and follow us on Twitter
@summitplc.
This announcement contains inside information for the purposes of
Article 7 of EU Regulation 596/2014 (MAR).
Contacts
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer, Corporate
Finance
Tom Salvesen, Corporate Broking
Bryan Garnier & Co Limited (Joint Broker) Tel: +44 (0)20 7332 2500
Phil Walker / Dominic Wilson
MSL Group (US) Tel: +1 781 684 6557
mailto:summit@mslgroup.com
Jon Siegal summit@mslgroup.com
---------------------------------
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Sue Stuart / Jessica mailto:summit@consilium-comms.com
Hodgson / summit@consilium-comms.com
---------------------------------
Lindsey Neville
Summit Forward-looking Statements
Any statements in this press release about the Company's future
expectations, plans and prospects, including but not limited to,
statements about the clinical and preclinical development of the
Company's product candidates, the therapeutic potential of the Company's
product candidates, the potential commercialisation of the Company's
product candidates, the sufficiency of the Company's cash resources, the
timing of initiation, completion and availability of data from clinical
trials, the potential submission of applications for marketing approvals
and other statements containing the words "anticipate," "believe,"
"continue," "could," "estimate," "expect," "intend," "may," "plan,"
"potential," "predict," "project," "should," "target," "would," and
similar expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors,
including: the uncertainties inherent in the initiation of future
clinical trials, availability and timing of data from ongoing and future
clinical trials and the results of such trials, whether preliminary
results from a clinical trial will be predictive of the final results of
that trial or whether results of early clinical trials or preclinical
studies will be indicative of the results of later clinical trials,
expectations for regulatory approvals, laws and regulations affecting
government contracts and funding awards, availability of funding
sufficient for the Company's foreseeable and unforeseeable operating
expenses and capital expenditure requirements and other factors
discussed in the "Risk Factors" section of filings that the Company
makes with the Securities and Exchange Commission, including the
Company's Annual Report on Form 20-F for the fiscal year ended 31
January 2018. Accordingly, readers should not place undue reliance on
forward-looking statements or information. In addition, any
forward-looking statements included in this press release represent the
Company's views only as of the date of this release and should not be
relied upon as representing the Company's views as of any subsequent
date. The Company specifically disclaims any obligation to update any
forward-looking statements included in this press release.
-END-
(END) Dow Jones Newswires
April 03, 2019 07:00 ET (11:00 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2023 to Apr 2024